Authors
Latest:
Sunvozertinib Shows Promise in Treating Pretreated EGFR+ Lung CancerXiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.
Latest:
Clinical Implications and Positioning of Imetelstat in Lower-Risk MDSClosing remarks on the overall clinical implications of imetelstat data, and patient populations that could benefit the most from it.
Latest:
Discussing Treatment Options for Patients With HCCJoan Culpepper-Morgan, MD, provides an overview on different treatment approaches for patients with hepatocellular carcinoma.
Latest:
How AI is Revolutionizing MDS DiagnosisPalak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.
Latest:
Multiple Myeloma Treatment Paradigm Improved Markedly In Recent YearsKenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.
Latest:
Unmet Needs of AML and Advice for Community OncologistsCourtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.
Latest:
Apa-RP Study Suggests Potential for Apalutamide and ADT in Prostate CancerVitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate CancerBarry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
Latest:
Next Steps for Trastuzumab Emtansine After the KAMILLA TrialRachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Latest:
About the Phase 3 SunRISe-5 Study of TAR-200Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this patient population.
Latest:
Graff on Using the Signatera Assay to Assess ctDNA in Early Breast CancerStephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Williams on the Phase 3 SunRISe-2 Study of TAR-200/Cetrelimab in MIBCStephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Latest:
Using ctDNA in Stage II Colon CancerCristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Latest:
Enhancing Patient-Centered Prostate Cancer Care CoordinationA discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.
Latest:
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial DataIn the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
Latest:
Machine Learning Transforms Multicancer Detection TestsThis review discusses the current state of multicancer early detection tests, the role of machine learning in their development, and their implications for oncology practice and patient care.
Latest:
Clinical Case – A Patient With Steroid-Refractory cGVHDA panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting multiple organ systems, including the skin (rash, itching), gastrointestinal tract (diarrhea, nausea, abdominal pain), liver (elevated enzymes, jaundice), and lungs (shortness of breath, cough), with severity assessment typically following established criteria.
Latest:
Risk-Adapted Study Enhances Response to IDH2-Targeted Therapy for AMLSheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.
Latest:
DuMontier Discusses Frailty in Newly Diagnosed Multiple MyelomaClark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.
Latest:
Breast Cancer Study Shows Minimal Score Variation After Radiation BoostFiras Eladoumikdachi, MD, FACS, and M. Michele Blackwood, MD, FACS, assess preoperative radiation boosts in breast cancer care.
Latest:
DLBCL Subtype Response Patterns: Optimizing Treatment SelectionExperts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) subgroups, including updates to published data. They also explore how different molecular classification methods compare in clinical practice to guide treatment selection, with insights on differential responses across specific molecular or clinical subgroups.
Latest:
Lean Six Sigma in Oncology: Insights From Waterhouse and MendenhallDavid M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed clinical operations and elevated the quality of patient care.
Latest:
Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable RiskAlan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.
Latest:
Kantarjian on Solutions for Oncology Drug ShortagesAccording to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.
Latest:
Olaparib Plus Abiraterone/Prednisone Improves Survival in mCRPCA promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.
Latest:
About the Phase 1/2 Study of IGV-001 in GlioblastomaDeric Park, MD, discusses a phase 1/2 study of IGV-001, a novel treatment for glioblastoma.
